Following their review of clinical trial data presented at SABCS 2023, the Oncology Brothers discuss their key takeaways on recent updates in HER2+ breast cancer.
FDA Clears IND of BTX-9341 in HR+/HER2- Breast Cancer
With the clearance of an investigational new drug application for BTX-9341 from the FDA, a phase 1 trial will evaluate the agent in HR-positive/HER2-negative breast cancer.
Read More
The Importance of Trastuzumab Deruxtecan in HER2+ Breast Cancer Treatment
In season 4, episode 2 of Targeted Talks, Sara A. Hurvitz, MD, discusses key advances in the HER2-positive breast cancer space and interesting ongoing research, namely trastuzumab deruxtecan.
Listen
USPSTF Lowers Age for Recommended Breast Cancer Screening to 40
Finalized breast cancer screening recommendations from the United States Preventive Services Task Force suggest women aged 40 to 74 should get a mammogram every other year.
Treating HER2-Positive Beast Cancer in the Community Setting
In season 3, episode 8 of Targeted Talks, Christie J. Hilton, DO, discusses treating first- and second-line HER2-positive breast cancer.
FDA Approves HLX02, Biosimilar Trastuzumab, for HER2-Positive Cancers
Trastuzumab-strf, a biosimilar of trastuzumab, has received FDA approval for treating HER2-overexpressing breast cancer and metastatic gastric cancer.
T-DXd Shows Significant PFS Improvement in HR+/HER2-Low Breast Cancer
New data from the DESTINY-Breast06 trial indicate that trastuzumab deruxtecan could become a new standard of care for patients with HER2-low and HER2-ultralow metastatic breast cancer.